SELLAS Life Sciences Group, Inc.
NASDAQ:SLSBiotechnology
+$0.31 today
- Market cap
- $3.66B
- Beta
- 2.53
- P/E (TTM)
- -47.3
- EPS (TTM)
- -$0.17
Volume 35.53M
Average 7.79M
SLS Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
SELLAS Life Sciences Group, Inc.NASDAQ: SLS
Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026
Cash & equivalents rises 203.3% from a year ago
Cash & equivalents stood at $134.71M at the end of Q3 FY2026, up 203.3% from a year earlier and down 2.7% from the prior quarter. Over 3 fiscal years it compounded at +61.3% a year.
Context
- Cash & equivalents amounted to 95.5% of total assets at the end of Q3 FY2026, up 9.3 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +203.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 71.89M USD
- Year-over-year change
- +417.7%
- 4-year CAGR
- +35.3%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 71.89M | +417.7% |
| FY2024 | 2024-12-31 | 13.89M | +448.9% |
| FY2023 | 2023-12-31 | 2.53M | -85.2% |
| FY2022 | 2022-12-31 | 17.13M | -20.2% |
| FY2021 | 2021-12-31 | 21.46M | — |
Cash & Equivalents vs competitors
How SLS compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +203.3% is the 3rd highest of 11, against a peer median of +22.9%.
- Cash & equivalents amounts to 95.5% of total assets for SLS, versus a peer median of 36.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $3.98B USD | +103.7% | +1.6% | 50.6% | |
AAPGAscentage Pharma Group International | Dec 2025 | CN¥2.47B CNY | +99.9% | +18.8% | 62.3% |
| Aug 2026 | $720.24M USD | +818.2% | +56.5% | 60.3% | |
| Sep 2026 | $212.84M USD | -21.9% | +218.0% | 42.1% | |
| Mar 2026 | $189.16M USD | +3269.4% | +64.5% | 95.0% | |
| Mar 2026 | $157.52M USD | +21.2% | +18.0% | 15.3% | |
| Sep 2026 | $134.71M USD | +203.3% | +61.3% | 95.5% | |
| Mar 2026 | $66.52M USD | -54.3% | -19.3% | 30.5% | |
| Mar 2026 | $62.1M USD | +24.5% | -34.7% | 17.8% | |
| Mar 2026 | $61.27M USD | +19.5% | +35.9% | 18.6% | |
| Mar 2026 | $21.76M USD | -46.0% | +4.8% | 18.2% | |
| Peer median (excluding SLS) | — | +22.9% | +18.4% | 36.3% | |
Competitors are the stored peer set for SLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 21.46M | 17.13M | 2.53M | 13.89M | 71.89M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 27K | 330K | 100K | 100K | 223K |
| Total Current Assets | 23.04M | 17.76M | 3.17M | 16.33M | 75.21M |
| Property, Plant & Equipment (Net) | 723K | 874K | 858K | 925K | 963K |
| Goodwill | 1.91M | 1.91M | 1.91M | 1.91M | 1.91M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | (184K) | 0 | 0 | 0 |
| Tax Assets | 152K | 184K | 0 | 0 | 0 |
| Other Non-current Assets | 594K | 399K | 275K | 466K | 257K |
| Total Non-current Assets | 3.38M | 3.19M | 3.05M | 3.31M | 3.13M |
| Total Assets | 26.43M | 20.94M | 6.22M | 19.43M | 78.35M |
| Account Payables | 2.14M | 3.36M | 5.64M | 3.5M | 2.95M |
| Short-term Debt | 198K | 0 | 0 | 0 | 544K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.65M | 5.5M | 1.54M | 1.82M | 1.77M |
| Total Current Liabilities | 4.98M | 15.52M | 13.74M | 9.51M | 7.02M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 152K | 184K | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | (184K) | 0 | 0 | 0 |
| Other Non-current Liabilities | 336K | 4K | 0 | 0 | 0 |
| Total Non-current Liabilities | 1.1M | 577K | 460K | 457K | 457K |
| Total Liabilities | 6.08M | 16.09M | 14.2M | 9.97M | 7.47M |
| Common Stock | 2K | 2K | 3K | 7K | 15K |
| Retained Earnings | (138.6M) | (179.9M) | (217.24M) | (248.13M) | (274.99M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 20.35M | 4.85M | (7.98M) | 9.47M | 70.87M |
| Total Debt | 808K | 945K | 906K | 1M | 1M |
| Net Debt | (20.65M) | (16.18M) | (1.62M) | (12.89M) | (70.89M) |
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
Intrinsic Alpha fair value
Locked
Current Price
$17.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.